FIT’s DNA plasmid will be combined with IVT’s delivery platform.
FIT Biotech and ImmunoVaccine Technologies (IVT) entered a preclinical research partnership to combine FIT’s anti-HIV DNA plasmid with IVT’s vaccine delivery system, DepoVax. GTU MiltiHIV is a synthetic DNA plasmid that covers the antigenic variability within HIV strains, attempting to counteract HIV’s known ability to mutate rapidly and therefore avoid effective vaccine therapy.
“DepoVax will act as a vector to deliver FIT Biotech’s GTU MultiHIV DNA vaccine, and our goal is to develop a more sophisticated and efficient HIV vaccine candidate,” says Marc Mansour, Ph.D., vp of R&D at IVT. DepoVax is a vaccine delivery system that delivers DNA plasmids into lymph nodes using liposomes to encapsulate a target antigen.
Related News from IVT
La Jolla Institute to Test IVT’s Delivery Platform with Infectious Disease Candidates (Mar. 27, 2009)
ImmunoVaccine Technologies Receives Funding to Further Cancer and Infectious Disease Vaccine Development (Jan. 21, 2008)
ImmunoVaccine Technologies to Take Over Immunotope (Dec. 10, 2007)